CD22 and hematologic disorder: In a phase 1 clinical trial in which children and young adults with relapsed/refractory CD22+ hematologic malignancies treated with anti-CD22 CAR-T cells were included, Jess J. et al. examined the hematologic toxicity profile of CAR-T cells and associations with neurotoxicity [48].